# Regimen Reference Order <br> LEUK - CALGB 10403 (Delayed Intensification) <br> ARIA: LEUK - [CALGB 10403 (Del Intens)] <br> ARIA Support: LEUK - [CALGB 10403(Del Int) IT] 

Planned Course: $\quad$ Single cycle ( 1 Cycle $=50$ days)
Indication for Use: Newly Diagnosed Precursor B-Cell Acute Lymphoblastic Leukemia
CVAD: Preferred (VESICANT INVOLVED)

## Proceed with treatment if:

Days 1 and 29
ANC equal to or greater than $0.75 \times 10^{9} / L$ AND Platelets equal to or greater than $75 \times 10^{9} / L$ * Contact Leukemia/BMT (L/BMT) Physician if parameters not met

## SEQUENCE OF MEDICATION ADMINISTRATION

| Pre-treatment Requirements |  |  |
| :---: | :---: | :---: |
| Drug | Dose | CCMB Administration Guideline |
|  | Not Applicable |  |

Treatment Regimen - LEUK - CALGB 10403 (Delayed Intensification)
Establish primary solution $\mathbf{5 0 0} \mathbf{~ m L}$ of: normal saline

| Drug | Dose | CCMB Administration Guideline |
| :---: | :---: | :---: |
| Day 1 |  |  |
| ondansetron | 16 mg | Orally 30 minutes pre-chemotherapy |
| vinCRIStine | $1.5 \mathrm{mg} / \mathrm{m}^{2}$ <br> maximum dose 2 mg | IV in normal saline 25 mL over 2 to 3 minutes by gravity infusion |
| DOXOrubicin | $25 \mathrm{mg} / \mathrm{m}^{2}$ | IV push over 10 minutes |
| dexamethasone | $5 \mathrm{mg} / \mathrm{m}^{2}$ <br> (round to nearest 2 mg ) (see Appendix B for dexamethasone dosing instructions) | Orally twice daily with food (Self-administered at home) |
| Days 2 and 3 |  |  |
| dexamethasone | $5 \mathrm{mg} / \mathrm{m}^{2}$ <br> (round to nearest 2 mg ) (see Appendix B for dexamethasone dosing instructions) | Orally twice daily with food (Self-administered at home) |


| Day 4 |  |  |
| :---: | :---: | :---: |
| dexamethasone | $5 \mathrm{mg} / \mathrm{m}^{2}$ <br> (round to nearest 2 mg ) (see Appendix B for dexamethasone dosing instructions) | Orally twice daily with food (Self-administered at home) |
| acetaminophen | 650 mg | Orally 1 hour prior to pegaspargase |
| hydrocortisone | 100 mg | IV in normal saline 50 mL over 15 minutes $\mathbf{1}$ hour prior to pegaspargase <br> *Nursing Alert: pegaspargase starts 1 hour after completion of hydrocortisone |
| famotidine | 20 mg | IV in normal saline 50 mL over 15 minutes |
| diphenhydrAMINE | 50 mg | IV in normal saline 50 mL over 15 minutes |
| Wait 30 minutes after completion of IV pre-medication(s) before starting pegaspargase |  |  |
| pegaspargase | $1000 \text { units } / \mathrm{m}^{2} \text {; }$ <br> maximum dose 1875 units | IV in normal saline 100 mL over 1 hour |
| Days 5 to 7 |  |  |
| dexamethasone | $5 \mathrm{mg} / \mathrm{m}^{2}$ <br> (round to nearest 2 mg ) (see Appendix B for dexamethasone dosing instructions) | Orally twice daily with food (Self-administered at home) |
| Day 8 |  |  |
| ondansetron | 16 mg | Orally 30 minutes pre-chemotherapy |
| vinCRIStine | $1.5 \mathrm{mg} / \mathrm{m}^{2} \text {; }$ <br> maximum dose 2 mg | IV in normal saline 25 mL over 2 to 3 minutes by gravity infusion |
| DOXOrubicin | $25 \mathrm{mg} / \mathrm{m}^{2}$ | IV push over 10 minutes |
| Day 15 |  |  |
| ondansetron | 16 mg | Orally 30 minutes pre-chemotherapy |
| vinCRIStine | $1.5 \mathrm{mg} / \mathrm{m}^{2}$; <br> maximum dose 2 mg | IV in normal saline 25 mL over 2 to 3 minutes by gravity infusion |
| DOXOrubicin | $25 \mathrm{mg} / \mathrm{m}^{2}$ | IV push over 10 minutes |
| dexamethasone | $5 \mathrm{mg} / \mathrm{m}^{2}$ <br> (round to nearest 2 mg ) (see Appendix B for dexamethasone dosing instructions) | Orally twice daily with food (Self-administer ed at home) |

## Days 16 to 21

| dexamethasone | $5 \mathrm{mg} / \mathrm{m}^{2}$ <br> (round to nearest 2 mg ) <br> (see Appendix B for <br> dexamethasone dosing <br> instructions) | Orally twice daily with food <br> (Self-administered at home) |
| :--- | :--- | :--- |

## Day 29

| normal saline | 1000 mL | IV over 1 hour (Pre hydration) |
| :--- | :--- | :--- |
| aprepitant | 125 mg | Orally 1 hour pre-chemotherapy |
| ondansetron | 16 mg | Orally 30 minutes pre-chemotherapy |
| dexamethasone | 12 mg | Orally 30 minutes pre-chemotherapy |
| cyclophosphamide | $1000 \mathrm{mg} / \mathrm{m}^{2}$ | IV in normal saline 250 mL over 1 hour |
| cytarabine | $75 \mathrm{mg} / \mathrm{m}^{2}$ | IV push over 2 to 5 minutes |
| thioguanine | $60 \mathrm{mg} / \mathrm{m}^{2}$ <br> (see Appendix $A$ and <br> Appendix $B$ for <br> thioguanine dosing <br> instructions) | Orally once on an empty stomach <br> Do not crush or chew <br> (Self-administered at home) |

## Days 30 to 32

| cytarabine | $75 \mathrm{mg} / \mathrm{m}^{2}$ | IV push over 2 to 5 minutes |
| :--- | :--- | :--- |
| thioguanine | $60 \mathrm{mg} / \mathrm{m}^{2}$ <br> (see Appendix $A$ and <br> Appendix $B$ for <br> thioguanine dosing <br> instructions) | Orally once daily on an empty stomach <br> Do not crush or chew <br> (Self-administered at home) |

## Days 33 to 35

| thioguanine | $60 \mathrm{mg} / \mathrm{m}^{2}$ <br> (see Appendix $A$ and <br> Appendix $B$ for <br> thioguanine dosing <br> instructions) | Orally once daily on an empty stomach <br> Do not crush or chew <br> (Self-administered at home) |
| :--- | :--- | :--- |
| Days $\mathbf{3 6}$ to $\mathbf{3 9}$ | cytarabine $\mathbf{7 5 \mathrm { mg } / \mathrm { m } ^ { 2 }}$ <br> (see Appendix $\mathbf{A}$ and <br> Appendix $B$ for <br> thioguanine dosing <br> instructions) Orally once daily on an empty stomach <br> Do not crush or chew <br> (Self-administered at home) <br> thioguanine IV push over $\mathbf{2}$ to 5 minutes  |  |

## Days 40 to 42

| thioguanine | $60 \mathrm{mg} / \mathrm{m}^{2}$ <br> (see Appendix $A$ and <br> Appendix $B$ for <br> thioguanine dosing <br> instructions) |
| :--- | :--- |

Orally once daily on an empty stomach
Do not crush or chew
(Self-administered at home)

## Day 43

| vinCRIStine | $1.5 \mathrm{mg} / \mathrm{m}^{2} ;$ <br> maximum dose 2 mg | IV in normal saline 25 mL over 2 to 3 minutes by gravity <br> infusion |
| :--- | :--- | :--- |
| acetaminophen | 650 mg | Orally $\mathbf{1}$ hour prior to pegaspargase |
| hydrocortisone | 100 mg | IV in normal saline 50 mL over 15 minutes $\mathbf{1}$ hour prior to <br> pegaspargase <br> *Nursing Alert: pegaspargase starts $\mathbf{1}$ hour after <br> completion of hydrocortisone |
| famotidine | 20 mg | IV in normal saline 50 mL over 15 minutes |
| diphenhydrAMINE | 50 mg | IV in normal saline 50 mL over 15 minutes |

Wait 30 minutes after completion of IV pre-medication(s) before starting pegaspargase

| pegaspargase | 1000 units $/ \mathrm{m}^{2} ;$ <br> maximum dose 1875 <br> units | IV in normal saline 100 mL over 1 hour |
| :--- | :--- | :--- |
| Day $\mathbf{5 0}$ |  |  |
| vinCRIStine | $1.5 \mathrm{mg} / \mathrm{m}^{2} ;$ <br> maximum dose 2 mg | IV in normal saline 25 mL over 2 to 3 minutes by gravity <br> infusion |

Patients will receive methotrexate Intrathecal Therapy with this regimen
(See Appendix C - Intrathecal Therapy (IT))

## See Appendix D - Delayed Intensification Dosing Schema

thioguanine (LANVIS ${ }^{\circledR}$ ) available dosage strength: 40 mg tablet
Classification: Cytotoxic, Hazardous

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

## REQUIRED MONITORING

## Cardiac Monitoring

- Left Ventricular Ejection Fraction (LVEF) monitoring is recommended at baseline and as clinically indicated


## Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin and glucose as per Physician Orders
- Glucose and lipase as per Physician Orders


## Day 4

- Fibrinogen as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and $\mathrm{O}_{2}$ saturation) at baseline and as clinically indicated during pegaspargase administration
- Observe patient for 1 hour after administration of pegaspargase. Full vital signs before discharge


## Days 15, 36 and 50

- Glucose and lipase as per Physician Orders


## Day 29

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin and glucose as per Physician Orders


## Day 43

- Fibrinogen, glucose and lipase as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and $\mathrm{O}_{2}$ saturation) at baseline and as clinically indicated during pegaspargase administration
- Observe patient for 1 hour after administration of pegaspargase. Full vital signs before discharge

|  | Recommended Support Medications |  |
| :--- | :--- | :--- |
| Drug | Dose | CCMB Administration Guideline |
| valACYClovir | 500 mg | Orally twice daily |
| sulfamethoxazole- <br> trimethoprim | $800 / 160 \mathrm{mg}$ | Orally once daily on Mondays, Wednesdays and Fridays |
| aprepitant | 80 mg | Orally once daily on Days 30 and 31 |
| metoclopramide | 10 mg | Orally every 4 hours while awake on Days 9 and 10 |
| metoclopramide | $10-20 \mathrm{mg}$ | Orally every 4 hours as needed for nausea and vomiting <br> (excluding Days 9 and 10) |

## DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to:
- Continue taking anti-emetic(s) at home
- Maintain oral intake of 2000 mL (8 glasses) of fluid daily at home
- Empty bladder every 2 hours while awake and at bedtime for 24 hours after cyclophosphamide treatment
- Obtain immediate assistance as per your clinic's contact instructions if:
- Symptoms of hemorrhagic cystitis (e.g. dysuria, hematuria)
- Unable to drink recommended amount of fluid
- thioguanine and dexamethasone are cancer therapies in this treatment regimen. Remind patient to take thioguanine and dexamethasone at home. See Appendix $B$ for dexamethasone and thioguanine prescriptions
- thioguanine should not be taken with milk or citrus based products
- Remind patient to take valACYclovir (shingles prophylaxis) and sulfamethoxazole-trimethoprim (Pneumocystis jirovecii pneumonia prophylaxis) at home
- Instruct patient to hold sulfamethoxazole-trimethoprim on days when intrathecal methotrexate is administered
- Reinforce safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy


## ADDITIONAL INFORMATION

- Physician or designate must be on site in case of reactions to pegaspargase
- Do not administer on weekends or holidays
- pegaspargase can cause anaphylaxis. diphenhydrAMINE, hydrocortisone and EPINEPHrine must be available in case of reaction
- pegaspargase can cause serious side effects such as hemorrhage, pancreatitis and thrombotic events
- sulfamethoxazole-trimethoprim should not be administered on days when intrathecal methotrexate is administered due to potential drug interaction
- Total daily dose of dexamethasone is calculated and then divided twice daily. Since dexamethasone is rounded to the nearest 2 mg tablet, this may result in a higher dose in the morning than in the afternoon. Due to limitations in ARIA, the prescription for dexamethasone is built as "Take as Directed". When prescribing, the Admin Instructions must be modified to include the appropriate dose
- thioguanine is dosed with a weekly target dose of $420 \mathrm{mg} / \mathrm{m}^{2}$ (Days 29 to 42). Doses are given at least one hour after the evening meal. Different daily doses rounded to the nearest 20 mg are to be given on alternating days when required to attain the weekly target dose. See Appendix A for administration instructions for thioguanine prescriptions
- pegaspargase dose reduction is recommended for patients with fatty liver or BMI over $30 \mathrm{~kg} / \mathrm{m}^{2}$ (dose reduce to pegaspargase 500 units $/ \mathrm{m}^{2}$ )
- thioguanine may be eligible for Home Cancer Drug Program coverage
- Intrathecal therapy is part of this regimen to start on Day 1 of CALGB 10403 (Delayed Intensification). See Appendix C regarding dosing for the support regimen LEUK - [CALGB 10403(Del Int) IT]. Support protocol is available under CALGB (Del Int IT) in the "Leukemia" folder


## Appendix A

## thioguanine Dosing - LEUK - CALGB 10403 (Delayed Intensification)

## thioguanine dose is calculated by the Leukemia/BMT clinic

In the LEUK - CALGB 10403 (Delayed Intensification) regimen, thioguanine should be dosed at $60 \mathrm{mg} / \mathrm{m}^{2} /$ day on Days 29 to 42 of the 50-day cycle (Weekly dose of $420 \mathrm{mg} / \mathrm{m}^{2}$ ). Because thioguanine is only available as a 40 mg tablet, there is limited flexibility in delivering the appropriate daily dose. As such, the dosing schedule may require different daily doses to ensure an appropriate dose over the course of the cycle.

While the Medical Oncology Manager (ARIA ${ }^{\circledR}$ ) application is used for order entry and a specific regimen for the LEUK - CALGB 10403 (Delayed Intensification) regimen is available, the dosing instructions for this regimen are too complex to build into the ARIA-based regimen. Manual calculation and manual entry of the dosing instructions (e.g. number of tablets per dose) is required. The table below outlines required tablets per dose according to patient body surface area.

Administration Instructions on Day 29:
Take dose orally once daily for 14 days starting Day 29
Take on an empty stomach at least one hour after the evening meal
Avoid milk and citrus based products at the same time as the dose

Target dose $=60 \mathrm{mg} / \mathrm{m}^{2}$ PO on Days 29 to 42 (Weekly dose $420 \mathrm{mg} / \mathrm{m}^{2} /$ week)

Medication may be eligible for Home Cancer Drug Program coverage

## thioguanine Dosing Instructions

| thioguanine dosing for daily doses of $60 \mathrm{mg} / \mathrm{m}^{2}$ (Target weekly dose of $420 \mathrm{mg} / \mathrm{m}^{2}$ ) administered on Days 29 to 42 |  |  |
| :---: | :---: | :---: |
| $\begin{aligned} & \text { BSA } \\ & \left(\mathrm{m}^{2}\right) \end{aligned}$ | $\begin{gathered} \text { 7-day daily } \\ \text { dose* } \\ 1 \text { tab }=40 \mathrm{mg} \end{gathered}$ | Dosing Instructions for Days 29 to 42** |
| 1.2-1.24 | 2 tablets/day x 4; <br> $11 / 2$ tablets/day $\times 3$ <br> ( $500 \mathrm{mg} /$ week) | Take 60 mg ( 1 \& $1 / 2$ tablets) once daily on Mondays, Wednesdays and Fridays and 80 mg (2 tablets) once daily on Tuesdays, Thursdays, Saturdays and Sundays <br> Qty: 25 of 40 mg tablets |
| 1.25-1.29 | 2 tablets/day x 5; <br> $11 / 2$ tablets/day x 2 <br> ( $520 \mathrm{mg} /$ week) | Take 60 mg ( 1 \& $1 / 2$ tablets) once daily on Thursdays and Sundays and 80 mg ( 2 tablets) once daily on Mondays, Tuesdays, Wednesdays, Fridays and Saturdays <br> Qty: $26 \times 40 \mathrm{mg}$ tablets |
| 1.3-1.34 | 2 tablets/day x 6; <br> $11 / 2$ tablets/day x 1 <br> ( $540 \mathrm{mg} /$ week) | Take 60 mg (1 \& 1/2 tablets) once daily on Thursdays and 80 mg (2 tablets) once daily on Mondays, Tuesdays, Wednesdays, Fridays, Saturdays and Sundays <br> Qty: $27 \times 40 \mathrm{mg}$ tablets |
| 1.35-1.39 | 2 tablets/day x 7 ( $560 \mathrm{mg} /$ week) | Take 80 mg (2 tablets) orally once daily Qty: $28 \times 40 \mathrm{mg}$ tablets |
| 1.4-1.44 | 2 tablets/day x 6; <br> 2 $1 / 2$ tablets/day $\times 1$ <br> ( $580 \mathrm{mg} /$ week) | Take 100 mg (2 \& 1/2 tablets) once daily on Thursdays and 80 mg (2 tablets) once daily on Mondays, Tuesdays, Wednesdays, Fridays, Saturdays and Sundays <br> Qty: $29 \times 40 \mathrm{mg}$ tablets |
| 1.45-1.49 | $\begin{aligned} & 2 \text { tablets/day } \times 5 ; \\ & 21 / 2 \text { tablets/day } \times 2 \\ & (600 \mathrm{mg} / \text { week }) \end{aligned}$ | Take 100 mg (2 \& 1/2 tablets) once daily on Thursdays and Sundays and 80 mg (2 tablets) once daily on Mondays, Tuesdays, Wednesdays, Fridays and Saturdays <br> Qty: $30 \times 40 \mathrm{mg}$ tablets |
| 1.5-1.54 | $\begin{aligned} & 2 \text { tablets/day } \times 4 ; \\ & 21 / 2 \text { tablets/day } \times 3 \\ & \text { (620 mg/week) } \end{aligned}$ | Take 100 mg ( $2 \& 1 / 2$ tablets) once daily on Mondays, Wednesdays and Fridays and 80 mg ( 2 tablets) once daily on Tuesdays, Thursdays, Saturdays and Sundays <br> Qty: $31 \times 40 \mathrm{mg}$ tablets |
| 1.55-1.59 | $21 / 2$ tablets day $\times 4$; <br> 2 tablets/day x 3 <br> ( $640 \mathrm{mg} /$ week) | Take 80 mg (2 tablets) once daily on Mondays, Wednesdays and Fridays and 100 mg ( $2 \& 1 / 2$ tablets) once daily on Tuesdays, Thursdays, Saturdays and Sundays <br> Qty: $32 \times 40 \mathrm{mg}$ tablets |
| 1.6-1.64 | $\begin{aligned} & 2 ½ \text { tablets/day } \times 5 \text {; } \\ & 2 \text { tablets/day } \times 2 \\ & (660 \mathrm{mg} / \text { week }) \end{aligned}$ | Take 80 mg (2 tablets) once daily on Thursdays and Sundays and 100 mg (2 \& $1 / 2$ tablets) once daily on Mondays, Tuesdays, Wednesdays, Fridays and Saturdays <br> Qty: $33 \times 40 \mathrm{mg}$ tablets |


| 1.65-1.69 | ```21/2 tablets/day x 6; 2 tablets/day x } (680 mg/week)``` | Take 80 mg (2 tablets) once daily on Thursdays and 100 mg ( $2 \& 1 / 2$ tablets) once daily on Mondays, Tuesdays, Wednesdays, Fridays, Saturdays and Sundays <br> Qty: $34 \times 40 \mathrm{mg}$ tablets |
| :---: | :---: | :---: |
| 1.7-1.74 | 212 tablets/day x 7 <br> ( $700 \mathrm{mg} /$ week) | Take 100 mg (2 \& 1/2 tablets) orally once daily Qty: $35 \times 40 \mathrm{mg}$ tablets |
| 1.75-1.79 | $\begin{aligned} & 2 ½ \text { tablets/day x } 6 ; \\ & 3 \text { tablets/day } \times 1 \\ & \text { (720 mg/week) } \end{aligned}$ | Take 120 mg (3 tablets) once daily on Thursdays and 100 mg ( $2 \& 1 / 2$ tablets) once daily on Mondays, Tuesdays, Wednesdays, Fridays, Saturdays and Sundays <br> Qty: $36 \times 40 \mathrm{mg}$ tablets |
| 1.8-1.84 | $\begin{aligned} & 2 ½ \text { tablets/day x 5; } \\ & 3 \text { tablets/day x } 2 \\ & \text { (740 mg/week) } \end{aligned}$ | Take 120 mg (3 tablets) once daily on Thursdays and Sundays and 100 mg (2 \& $1 / 2$ tablets) once daily on Mondays, Tuesdays, Wednesdays, Fridays and Saturdays <br> Qty: $37 \times 40 \mathrm{mg}$ tablets |
| 1.85-1.89 | $\begin{aligned} & 21 / 2 \text { tablets/day x } 4 ; \\ & 3 \text { tablets/day x } 3 \\ & \text { ( } 760 \mathrm{mg} / \text { week) } \end{aligned}$ | Take 120 mg (3 tablets) once daily on Mondays, Wednesdays and Fridays and 100 mg (2 \& 1/2 tablets) once daily on Tuesdays, Thursdays, Saturdays and Sundays <br> Qty: $38 \times 40 \mathrm{mg}$ tablets |
| 1.9-1.94 | ```3 tablets/day x 4; 21/2 tablets/day x } (780 mg/week)``` | Take 100 mg ( 2 \& $1 / 2$ tablets) once daily on Mondays, Wednesdays and Fridays and 120 mg (3 tablets) once daily on Tuesdays, Thursdays, Saturdays and Sundays <br> Qty: $39 \times 40 \mathrm{mg}$ tablets |
| 1.95-1.99 | ```3 tablets/day x 5; 21/2 tablets/day x } (800 mg/week)``` | Take 100 mg ( 2 \& 1/2 tablets) once daily on Thursdays and Sundays and 120 mg (3 tablets) once daily on Mondays, Tuesdays, Wednesdays, Fridays and Saturdays <br> Qty: $40 \times 40 \mathrm{mg}$ tablets |
| 2-2.04 | 3 tablets/day x 6; <br> $21 / 2$ tablets/day x 1 <br> ( $820 \mathrm{mg} /$ week) | Take 100 mg ( 2 \& 1/2 tablets) once daily on Thursdays and 120 mg (3 tablets) once daily on Mondays, Tuesdays, Wednesdays, Fridays, Saturdays and Sundays <br> Qty: $41 \times 40 \mathrm{mg}$ tablets |
| * The 7-day daily dose refers to the weekly dose to attain the weekly target dose of $420 \mathrm{mg} / \mathrm{m}^{2}$ <br> ** Dosing Instructions for Day 29 can be used for the administration instruction field of the ARIA prescription for the relevant BSA. Required days of the week and dispensing quantities are included in the instructions. <br> Due to limitations in ARIA the prescription for thioguanine has a default dose of $1 \mathrm{mg} / \mathrm{m}^{2}$. When prescribing it is advised to modify the prescription from "Complex" to "Take as Directed" and to populate the Admin Instructions with the relevant instructions from this table (Dosing Instructions for Days 29 to 42) and Administration Instructions from Page 7. <br> Patients with thiopurine methyltransferase (TPMT) deficiency require dose reductions during therapy. Please refer to original protocol for details. (When myelosuppression has led to significant delays in therapy (greater than 2 weeks) or is disproportionate to the therapy, thiopurine methyltransferase testing should be performed) |  |  |

## Appendix B

| dexamethasone and thioguanine prescriptions |  |  |
| :---: | :---: | :---: |
| Drug | Dose | CCMB Administration Guideline |
| dexamethasone | $5 \mathrm{mg} / \mathrm{m}^{2}$ <br> (to nearest 2 mg ) | Orally twice daily with food on Days 1 to 7 and Days 15 to 21 |
| thioguanine | $60 \mathrm{mg} / \mathrm{m}^{2}$ <br> (see Appendix A <br> for thioguanine <br> dosing <br> instructions) | Orally once daily on an empty stomach on Days $\mathbf{2 9}$ to 42 Do not crush or chew |

## Appendix C

## Intrathecal Therapy (IT) - LEUK - [CALGB 10403(Del Int) IT]

Proceed with treatment if:

- Platelets equal to or greater than $50 \times 10^{9} / \mathrm{L}$

Days 1, 29 and 36

| Drug | Dose | CCMB Administration Guideline |
| :--- | :--- | :--- |
| methotrexate | 15 mg | Intrathecal in 6 mL preservative free normal saline administered <br> in L/BMT Clinic |

IT is ordered as a separate support regimen to start on Day 1 of CALGB 10403 (Delayed Intensification)

## Appendix D

## Delayed Intensification Dosing Schema

| Day | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| vinCRIStine $1.5 \mathrm{mg} / \mathrm{m}^{2} \mathrm{IV}$; maximum dose 2 mg |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| DOXOrubicin $25 \mathrm{mg} / \mathrm{m}^{2} \mathrm{IV}$ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| dexamethasone $5 \mathrm{mg} / \mathrm{m}^{2}$ orally twice daily |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| pegaspargase 1000 units $/ \mathrm{m}^{2}$ IV; maximum dose 1875 units |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |


| Day | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| vinCRIStine $1.5 \mathrm{mg} / \mathrm{m}^{2} \mathrm{IV}$; maximum dose 2 mg |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| pegaspargase 1000 units $/ \mathrm{m}^{2} \mathrm{IV}$; maximum dose 1875 units |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| cyclophosphamide $1000 \mathrm{mg} / \mathrm{m}^{2} \mathrm{IV}$ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| cytarabine $75 \mathrm{mg} / \mathrm{m}^{2} \mathrm{IV}$ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| thioguanine $60 \mathrm{mg} / \mathrm{m}^{2}$ orally once daily |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

Key:
indicates that this medication will be administered on this day

CancerCareManitoba
ActionCancerManitoba

